Advertisement

Synergy Over Monotherapy

  • Zuzana JežíkováEmail author
  • Tomáš Pagáč
  • Ján Víglaš
  • Barbora Pfeiferová
  • Katarína Šoltys
  • Helena Bujdáková
  • Lucia Černáková
  • Petra Olejníková
Article
  • 22 Downloads

Abstract

Pathogenic fungi, as an increasing global threat to human health, represent a sizable risk. However, significant attention should also be paid to the yeast biofilms. One promising strategy for combating resistant microbes, as well as fungal biofilms, is to extend the lifespan and efficacy of our currently employed drugs by using combination therapy. Since the application of combined therapy of fungal infections is currently accepted, we have decided to verify the efficacy of derivative H in combination with fluconazole on C. albicans biofilm. The main advantage of synergy over monotherapy lies in reducing or even completely preventing the induction of resistance of fungal cells. We have decided to verify the derivative H (1,4-dihydropyridine-2,3,5-tricarboxylate), an intermediate of nilvadipine synthesis, in the resistance of C. albicans to fluconazole. Therefore, we have focused on the influence of derivative H on the gene expression of the main C. albicans adhesin (ALS3), which is important for the tissue colonization during the infection process. Our results show that the newly synthesized derivative H had an impact on biofilm eradication. The effect of biofilm diminution could, therefore, be explained as derivative H preventing the adherence of C. albicans cells. This study supports even more the attractiveness of this substance as a potential agent that could be used in synergy with commonly used azoles to treat various fungal infections.

Notes

Acknowledgements

This work was supported by the Project APVV-0719-12 and VEGA Project 1/0697/18.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Shapiro RS, Robbins N, Cowen LE (2011) Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75(2):213–267.  https://doi.org/10.1128/MMBR.00045-10 CrossRefGoogle Scholar
  2. 2.
    Brown ED, Wright GD (2016) Antibacterial drug discovery in the resistance era. Nature 529(7586):336–343.  https://doi.org/10.1038/nature17042 CrossRefGoogle Scholar
  3. 3.
    Zimmermann GR, Lehár J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12(1–2):34–42CrossRefGoogle Scholar
  4. 4.
    Hill JA, Cowen LE (2015) Using combination therapy to thwart drug resistance. Future Microbiol 10(11):1719–1726.  https://doi.org/10.2217/fmb.15.68 CrossRefGoogle Scholar
  5. 5.
    Chudík L, Marchalín Š, Daïch A, Decroix B (2000) New synthesis of the calcium antagonist Nilvadipine. Res Adv Synth Org Chem 1:1–7Google Scholar
  6. 6.
    Ježíková Z, Pagáč T, Pfeiferová B, Bujdáková H, Dižová S, Jančíková I, Gášková D, Olejníková P (2017) Synergy between azoles and 1,4-dihydropyridine derivative as an option to control fungal infections. Antonie Van Leeuwenhoek 110(9):1219–1226.  https://doi.org/10.1007/s10482-017-0895-6 CrossRefGoogle Scholar
  7. 7.
    EUCAST (2017) European committee on antimicrobial susceptibility testing. http://www.eucast.org. Accessed Aug 2018
  8. 8.
    Sherry L, Rajendran R, Lappin DF, Borghi E, Perdoni F, Falleni M, Tosi D, Smith K, Williams C, Jones B et al (2014) Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiol 14:182.  https://doi.org/10.1186/1471-2180-14-182 CrossRefGoogle Scholar
  9. 9.
    Gullapalli S, Ramarao P (2002) L-type Ca2 + channel modulation by dihydropyridines potentiates kappa-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats. Neuropharmacology 42(4):467–475.  https://doi.org/10.1016/S0028-3908(01)00200-3 CrossRefGoogle Scholar
  10. 10.
    Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD (2016) Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol 7:2173.  https://doi.org/10.3389/fmicb.2016.02173 Google Scholar
  11. 11.
    Hoyer LL (2001) The ALS gene family of Candida albicans. Trends Microbiol 9(4):176–180CrossRefGoogle Scholar
  12. 12.
    Zhao X, Daniels KJ, Oh SH, Green CB, Yeater KM, Soll DR, Hoyer LL (2006) Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces. Microbiology 152(8):2287–2299CrossRefGoogle Scholar
  13. 13.
    Nobile CJ, Mitchell AP (2006) Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 8(9):1382–1391CrossRefGoogle Scholar
  14. 14.
    Nett JE, Lepak AJ, Marchillo K, Andes DR (2009) Time course global gene expression analysis of an in vivo Candida biofilm. J Infect Dis 200(2):307–313.  https://doi.org/10.1086/599838 CrossRefGoogle Scholar
  15. 15.
    Fanning S, Mitchell AP (2012) Fungal Biofilms. PLoS Pathog 8(4):e1002585.  https://doi.org/10.1371/journal.ppat.1002585 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Biochemistry and Microbiology, Faculty of Chemical and Food TechnologySlovak University of Technology in BratislavaBratislavaSlovakia
  2. 2.Comenius University Science ParkComenius UniversityBratislavaSlovakia
  3. 3.Department of Molecular Biology, Faculty of Natural SciencesComenius UniversityBratislava 4Slovakia
  4. 4.Department of Microbiology and Virology, Faculty of Natural SciencesComenius UniversityBratislava 4Slovakia

Personalised recommendations